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and 66 (37%) patients died during follow-up. Compared withHepatitis C virus genotype does not affect patient survival
patients infected with HCV genotype 1a, the relative risk (RR)among renal transplant candidates.
of death from all causes was not significantly increased amongBackground. Patients with end-stage renal disease (ESRD)
patients infected with genotype 1b (RR 5 1.02, 95% CI, 0.55are at increased risk for infection with different hepatitis C virus
to 1.89) or other genotypes (RR 5 1.08, 95% CI, 0.50 to 2.30).(HCV) genotypes and multiple genotype infections. However,
Likewise, compared with patients with a single infection, theto date, the effect of the type and number of infecting HCV
RR of death among patients with mixed infection (RR 5 1.18,genotypes on survival among ESRD patients has not been care-
95% CI, 0.52 to 2.66) was not significantly increased.fully examined, and this was the objective of this study.
Conclusions. The results of this study suggest that the typeMethods. Sera from patients on the renal transplant waiting
and number of HCV genotypes may not have a significantlist at the New England Organ Bank between November 1986
impact on survival among ESRD patients.and June 1990 were tested for anti-HCV using a third-genera-
tion enzyme-linked immunosorbent assay. All anti-HCV–
positive serum samples were tested for HCV RNA by reverse
transcriptase “nested” polymerase chain reaction (PCR) with Hepatitis C virus (HCV) infection is the leading causeprimers derived from the highly conserved 59UTR region of the
of chronic hepatitis and end-stage liver disease in theHCV genome. HCV genotypes were determined by restriction
United States [1, 2]. The determinants of the severityfragment length polymorphism of the 59UTR PCR product.
The duration of follow-up was calculated from the date of the and progression of chronic hepatitis C are incompletely
first available serum specimen until death, loss to follow-up, or understood [1, 2]. However, patient factors such as the
December 31, 1995, whichever occurred earlier. Two separate age, gender, race, immunodeficiency, and alcohol abuse,multivariate models were constructed: one to examine the im-
and viral factors such as duration of infection, presencepact of HCV genotype on mortality and the other to examine
and titer of serum HCV RNA, viral genotype, degreethe impact of the single versus mixed infection on mortality.
In both models, the independent variables were HCV genotype of genetic heterogeneity (quasispecies), and coinfection
and transplantation. The HCV genotype was treated as a time- with other viruses have been shown to play an important
independent (baseline) variable. Transplantation was treated role [1, 3]. In particular, the role of different HCV geno-as a time-dependent variable in which the status changed after
types in the observed differences in severity of liver dis-transplantation.
ease and response to therapy has drawn considerableResults. HCV RNA was detected by PCR in 224 patients
(81%) in whom sera were available. Complete clinical data on attention (abstract; Feray, Hepatology, 18:59, 1993) [4–6].
baseline covariates, subsequent transplantation, and mortality A number of HCV variants have been isolated by nucleo-
were available in 180 patients (80%), and these patients consti- tide sequence analysis of the viral genome. These variantstuted the final study cohort. HCV genotypes 1a and 1b were
have been classified into six major groups, sharing a meanthe two most common genotypes encountered and were found
sequence homology of 65% and being designated asin 60 and 24% of the patients, respectively. One hundred and
sixty-two (90%) patients were infected with a single HCV single HCV types [7]. Each type consists of two to three clusters
genotype, 16 patients (9%) with two genotypes, and two pa- of variants with a mean sequence homology of 80%,
tients (1%) with three genotypes. Among the 180 patients in designated as subtypes [7]. Finally, each subtype consiststhe final study cohort, 86 (48%) underwent transplantation,
of individual isolates, with a mean sequence homology
of 88% [7]. The clinical significance of the genomic diver-
sity of HCV has yet to be completely elucidated.Key words: chronic hepatitis, end-stage liver disease, transplantation,
viral infection, HCV genotype. Hepatitis C virus infection is an important cause of
morbidity and mortality among patients with end-stageReceived for publication December 17, 1998
renal disease (ESRD), particularly among renal trans-and in revised form February 15, 1999
Accepted for publication March 1, 1999 plant recipients [8]. We have previously demonstrated
that HCV infection at the time of referral for renal trans- 1999 by the International Society of Nephrology
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plantation is associated with an increased risk of death, linked immunosorbent assay (ELISA3; Ortho HCV
ELISA 3.0-test System; Ortho Diagnostics System, Rari-irrespective of whether patients remain on dialysis or
undergo transplantation [9]. Furthermore, among pa- tan, NJ, USA), which detects antibodies to recombinant
HCV antigens (c22, c200, NS5) derived from the non-tients referred for renal transplantation, the mortality
among those who underwent transplantation was not structural (NS3, NS4, NS5) and core regions of the viral
genome. The assay was performed by Ortho Diagnostics.increased compared with those who remained on dial-
ysis. In fact, for those who underwent renal transplanta- Hepatitis C virus RNA. All ELISA3-positive serum
samples were tested for HCV RNA by reverse tran-tion, the relative risk (RR) of death was increased only
during the first three months, but decreased significantly scriptase “nested” polymerase chain reaction (PCR) with
primers derived from the highly conserved 59UTR regionthereafter. These data suggested that anti-HCV–positive
status alone should not be a contraindication for renal of the HCV genome [11, 12].
Hepatitis C virus genotype. HCV genotypes were de-transplantation [9]. We have also shown that six different
HCV genotypes were represented among patients re- termined by restriction fragment length polymorphism
(RFLP) of the 59UTR PCR product. This method wasferred for renal transplantation to centers served by the
New England Organ Bank (NEOB), and several patients chosen because amplification of the 59UTR has been
shown to be the most efficient and, hence, genotypinghad infection with more than one genotype [10]. How-
ever, to date, the effect of the type and number of in- likely to be successful in the majority of the patients
studied. Briefly, 59UTR was reverse transcribed withfecting HCV genotypes on survival among ESRD pa-
tients has not been carefully examined and was the outer primers (antisense, 59-TCATGGTGCACGGTCT
ACGAGACCT-39; sense, 59-CTGTAGGAACTACTGobjective of this study.
TCTT-39) and inner primers (antisense, 59-CACTCGC
AAGCACCTATCAGGCAGT-39; sense, 59-TTCACG
METHODS
CAGAAAGCGTCTAG-39) as previously described
Patients [11, 12]. The amplification products were then digested
by two restriction enzymes, HaeIII/RsaI and Mval/Hinfl,The patient sample for this study was drawn from a
historical cohort selected to study the effect of anti-HCV in order to differentiate HCV into various major geno-
types (types 1 through 6). Subtypes 1a/c and 1b werestatus at the time of referral for transplantation and
treatment modality (dialysis vs. transplantation) on sub- further differentiated by restriction with the enzyme
BstUl. Subtypes 2a/c and 2b, as well as subtypes 3a andsequent mortality. Patients were drawn from all 14 trans-
plant centers in the six New England states served by 3b, were further differentiated by digestion with ScrFI.
The nomenclature proposed by Simmonds et al was usedthe NEOB. The details of study design and methods
for patient selection have been previously reported [9]. to classify HCV genotypes [7]. Previous studies have
shown that in samples obtained from patients in theBriefly, all patients on the renal transplant waiting list
between November 1986 and January 1987 (“prevalent” United States, most of the 1a/c samples were 1a, and 2a/c
samples were 2a (Lau, unpublished data). Hence, for thepopulation), as well as those referred for renal trans-
plantation between February 1987 and June 1990 (“inci- sake of simplicity, these samples were referred to as
1a and 2a, respectively. The presence of a single HCVdent” population), were identified from the tissue-typing
laboratory records of the NEOB. For prevalent patients, genotype was defined as a single infection, and infection
with more than one (two or three) HCV genotypes wasthe first serum sample available during the period be-
tween November 1986 and January 1987 was retrieved defined as a mixed infection.
for anti-HCV testing. For incident patients, the first se-
Clinical informationrum sample available within six months of referral for
transplantation was retrieved for anti-HCV testing. The Clinical data were collected from the NEOB records,
United Network for Organ Sharing Computer Services,anti-HCV positive cohort comprised all anti-HCV–posi-
tive patients. Recipients of living-related and cadaver ESRD Networks of New England and New York, data-
bases of the tissue-typing laboratories of Brigham anddonors were included. Recipients of kidneys from anti-
HCV–positive donors were not included. Women’s Hospital, Massachusetts General Hospital, and
Maine Medical Center, and hospital, transplant office,
Tests for hepatitis C virus infection and dialysis unit medical records at the participating
centers. Enrollment into the study was defined as theSerum samples stored at 2708C were retrieved from
the NEOB, as well as the tissue-typing laboratories at date of the first available serum specimen. Clinical infor-
mation collected at the time of enrollment included ageBrigham and Women’s Hospital, Massachusetts General
Hospital, and Maine Medical Center. at onset of renal replacement therapy, gender, race,
cause of ESRD, presence of diabetes mellitus, year ofAnti-hepatitis C virus antibody. All samples were tested
for anti-HCV antibody using third-generation enzyme- initiation of renal replacement therapy (dialysis or trans-
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plantation), date of listing for renal transplantation at of HCV genotype on mortality, the analysis was re-
stricted to patients with a single HCV infection, to avoidthe NEOB, dialysis modality, history of liver disease
and non-A, non-B hepatitis (NANBH), number of blood the possible effect of interactions between the different
HCV genotypes.transfusions, number of previous transplants, blood
group, panel reactive antibody (PRA) assay, hepatitis B Calculations were performed using SAS/Stat (version
6.12; SAS Institute Inc., Cary, NC, USA), except forsurface antigen (HBsAg), antibody to hepatitis B surface
antigen (anti-HBs), antibody to hepatitis B core antigen residual diagnostics, which were performed using S-Plus
version 3.3 for Windows (StatSci, a division of MathSoft(anti-HBc), antibody to cytomegalovirus (anti-CMV),
and serum alanine aminotransferase (ALT) and albumin Inc., Seattle, WA, USA).
levels. Serum ALT was considered elevated if it was
greater than two and a half times the upper limit of
RESULTS
normal. Follow-up information on date of transplanta-
Study population and distribution of hepatitis Ction, graft loss, and date and cause of death were ascer-
virus genotypestained. The duration of follow-up was calculated from
the enrollment date until death, loss to follow-up, or A total of 3,243 patients were identified as being pres-
ent on the renal transplant waiting list between Novem-December 31, 1995, whichever occurred earlier.
ber 1986 and January 1987 or were listed for renal trans-
Statistical analysis plantation between February 1987 and June 1990. Serum
for anti-HCV testing was available in 1544 (48%). TwoMultivariate analyses were performed using a Cox
proportional hazards model. Because this was an inten- hundred and eighty-seven patients (19%) tested positive
for anti-HCV by ELISA3. Extra serum samples weretion-to-treat analysis, patients who were removed from
the waiting list because of illness or complications were available in 275 (96%) of the ELISA3-positive patients.
HCV RNA was detected by PCR in 224 patients (81%),analyzed as if they remained on the waiting list from the
date of enrollment until the end of the follow-up. The in whom extra sera were available. Complete clinical
data on baseline covariates, subsequent transplantation,date of referral for transplantation could be ascertained
for the incident group, but not for the prevalent group. and mortality were available in 180 patients (80%), and
these patients constituted the final study cohort. HCVTherefore, patient survival was computed from the onset
of treatment for ESRD. Patients did not contribute to genotypes 1a, 1b, 2a, 2b, 3a, and 4 were found in 109
(60%), 44 (24%), 13 (7%), 22 (12%), 8 (4%), and 4the part of the survival curve during the interval between
onset of renal replacement therapy (that is, dialysis or (2%) of patients, respectively (the total is greater than
100% because some patients had more than one geno-transplantation) and enrollment into the study. Individ-
ual patient experience was therefore truncated on the left type). One hundred and sixty-two (90%) patients were
infected with a single HCV genotype, 16 patients (9%)and censored on the right [13]. Most patients contributed
information to the middle part of the survival curve. with two genotypes, and two patients (1%) with three
genotypes.Two separate multivariate survival models were con-
structed: one to examine the impact of HCV genotype
Hepatitis C virus genotype, transplantation, andon mortality and the other to examine the impact of
overall mortalitythe single versus mixed infection on mortality. In both
models, the independent variables were type or number Among the 180 patients in the final study cohort, the
median follow-up was 70 months (range 1 to 108 months).of HCV genotypes and transplantation. HCV genotype
was treated as a time-independent (baseline) variable. Eighty-six patients (48%) underwent transplantation,
and 66 (37%) died during follow-up. The all-cause mor-Transplantation was treated as a time-dependent vari-
able in which the status changed upon transplantation. tality among the patients infected with HCV genotype
1a, 1b, and all other genotypes was 33, 47, and 30%,All patients contributed information to the dialysis group
survival curve, but only those who underwent trans- respectively. Figure 1 shows the univariate survival curves
since initiation of renal replacement therapy of renalplantation contributed information to the transplant
group survival curve. The details of the development transplant candidates infected with HCV genotypes 1a,
1b, or all others. The all-cause mortality among patientsof these models have been previously reported [9]. In
addition, the two significant baseline covariates from with single or mixed infection was 36% and 44%, respec-
tively. Figure 2 shows the univariate survival curves sinceour previous analyses, age at onset of renal replacement
therapy and diabetes mellitus, were included in both initiation of renal replacement therapy of renal trans-
plant candidates infected with a single or mixed infection.models. Transplant center as a stratification variable was
not included in these models because its inclusion in the Multivariate analysis, adjusted for age at onset of renal
replacement therapy, diabetes mellitus, and transplanta-regression model did not affect the regression coeffi-
cients significantly. In the model that examined the effect tion status showed that compared with patients infected
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Table 1. Relative risk of death among HVC RNA positive patients
referred for renal transplantation—Effect of HCV genotype
All-cause mortality
Relative 95% confidence
Risk factor risk of death intervals
HCV genotype
1b vs. 1a 1.02 0.55–1.89
All othersa vs. 1a 1.08 0.50–2.30
Transplantation (vs. dialysis)
0–3 months post-transplantation 4.59 1.68–12.55
4–6 months post-transplantation 0.98 0.13–7.54
7–47 months post-transplantation 0.22 0.07–0.72
.48 months post-transplantation 0.81 0.35–1.89
Age at onset of RRTb per year 1.06 1.03–1.08
Diabetes mellitus (vs. non-diabetics) 1.35 0.63–2.90
a Includes HCV genotypes 2a, 2b, 3a and 4
b RRT, renal replacement therapy
Fig. 1. Survival since the initiation of renal replacement therapy among
renal transplant candidates infected with hepatitis C virus (HCV) geno-
Table 2. Relative risk of death among HVC RNA positive patientstypes 1a (heavy solid line), 1b (long dashed line), or all others (dotted
referred for renal transplantation—line).
Effect of single versus mixed genotype infection
All-cause mortality
Relative 95% confidence
Risk factor risk of death intervals
Mixed vs. single infection 1.18 0.52–2.66
Transplantation (vs. dialysis)
0–3 months post-transplantation 4.62 1.83–11.68
4–6 months post-transplantation 0.80 0.10–6.03
7–47 months post-transplantation 0.25 0.09–0.71
.48 months post-transplantation 0.84 0.38–1.86
Age at onset of RRT per year 1.05 1.03–1.08
Diabetes mellitus (vs. non-diabetics) 1.37 0.69–2.73
RRT is renal replacement therapy.
creased RR of death during the first three months, but
decreased significantly thereafter (Tables 1 and 2).
Fig. 2. Survival since the initiation of renal replacement therapy among DISCUSSION
renal transplant candidates infected with a single (solid line) or mixed
(dotted line) hepatitis C virus (HCV) infection. The role of HCV genotype in predicting long-term
clinical outcomes among nonimmunosuppressed patients
infected with HCV is still not completely elucidated [14].
The majority of studies have focused on the effect of
with HCV genotype 1a, the RR of death from all causes HCV genotypes 1 versus 2 and 1a versus 1b on the
was not significantly increased among patients infected severity of liver disease or response to treatment with
with genotype 1b (RR 5 1.02, 95% CI, 0.55 to 1.89) or interferon-a [4–6, 15]. In general, these studies have ob-
other genotypes (RR 5 1.08, 95% CI, 0.50 to 2.30; served that infection with genotype 1 is associated with
Table 1). Likewise, compared with patients with a single more severe liver disease compared with infection with
infection, the adjusted RR of death among patients with genotype 2, and within genotype 1, genotype 1b is associ-
a mixed infection (RR 5 1.18, 95% CI, 0.52 to 2.66; ated with more severe liver disease compared with geno-
Table 2) was not significantly increased. The RR of death type 1a (abstract; Feray, Hepatology 18:59, 1993) [4, 14].
from liver disease and/or infection was also not signifi- However, other investigators have found no significant
cantly different among patients with different genotype association between HCV genotype and severity of liver
infections and single versus mixed infection (data not disease (abstracts; Benvegnu, Hepatology 22:343A, 1995;
shown). Both multivariate models indicate that com- Romeo, Hepatology 24:153A, 1996) [15, 16] or response
pared with those who remained on dialysis, those who to interferon-a [16]. More importantly, the impact of
HCV genotypes on long-term patient survival has notunderwent renal transplantation had a significantly in-
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been rigorously examined, particularly among patients not significantly affect the regression coefficients, sug-
gesting that the differences in immunosuppressive andwith ESRD. In this study, we examined the distribution
of different HCV genotypes among ESRD patients re- management protocols at the different transplant centers
probably did not influence the results of this study.ferred for renal transplantation and the effect of HCV
genotypes on patient survival. Studies in humans and animals with HCV infection
have revealed a lack of protective immunity against rein-The predominance of HCV genotype 1a (60%) over
1b (24%) among renal transplant candidates in the New fection (new infection after the previous infection has
cleared) with the same or different genotype or superin-England region of the United States is in contrast to the
distribution of genotypes among ESRD patients in other fection (infection with a new genotype in presence of
pre-existing infection) [21–23]. Reinfection and superin-parts of the world. Indeed, among ESRD patients with
HCV infection in Europe, genotype 1b (53 to 65%) was fection have been reported in thalassemic children and
hemophiliacs after multiple blood transfusions [23, 24].more common than genotype 1a (3 to 10%) [17–19].
However, the distribution of HCV genotypes among The newly introduced HCV genotype may either replace
(“take over”), be eliminated, or coexist with the prede-ESRD patients in this study (HCV genotype 1a in 60%,
1b in 24%, 2a in 7%, 2b in 12%, 3a in 4%, and 4 in cessor HCV genotype. The clinical implications of each
of these virological outcomes are currently unclear.2%) bore a closer resemblance to the distribution among
nonrenal patients in the United States, in whom geno- Overall, mixed infections have been found in 0 to 4.5%
of the patients with HCV-associated liver disease [6,types 1a, 1b, 2a, 2b, 3 and 4 were observed in 36, 38, 6,
9, 6 and 1%, respectively [6]. These observations are in 25, 26]. However, among HCV-infected healthy blood
donors who do not abuse intravenous drugs, mixed infec-keeping with other studies that have shown that the
distribution of HCV genotypes among ESRD patients tions are exceedingly rare [5, 25, 27–32]. On the other
hand, a higher prevalence has been recognized amongcommonly reflects the prevalence of HCV genotypes in
the general population with chronic hepatitis C, in the hemophiliacs (14 to 18%) [25, 33] and hemodialysis pa-
tients (0 to 13%) [28, 29, 34, 35], implying that thesesame geographic region [19, 20]. The similarity in the
distribution of HCV genotypes among ESRD and non- populations are likely to be at a higher risk of acquiring
HCV infection with multiple genotypes. In our study,ESRD patients is most likely due to the fact that the
source of HCV infection was similar among the two infection with one, two, or three different HCV geno-
types was present in 90, 9, and 1%, respectively. How-groups, with the majority of patients having acquired the
infection from blood products prior to the implementa- ever, we did not observe a significant difference in sur-
vival between patients infected with single or multipletion of screening for anti-HCV.
Only limited data exist on the impact of HCV geno- HCV genotypes. This observation could have important
implications for development of dialysis unit and trans-type on the clinical course and outcomes of HCV infec-
tion in dialysis patients and renal transplant recipients. plant policies. ESRD patients with HCV infection are
at risk for mixed genotype infections from multiple bloodColleoni et al have reported that HCV genotype 1 was
associated with higher ALT levels, both in the acute transfusions, transmission in the dialysis unit (particu-
larly when isolated with other HCV-positive patients),phase and after more than 10 years of HCV infection.
However, liver biopsies were not performed in this study, or transmission by transplantation of a kidney from a
HCV-positive donor. Because the risk of infection fromand therefore, the severity of liver disease could not be
ascertained [19]. More recently, among renal transplant blood transfusion is no longer a major threat [36], the
results of this study are particularly important in therecipients with HCV infection with a mean post-trans-
plantation follow-up of more than five years, Rostaing latter two situations.
Isolation of anti-HCV–positive dialysis patients to pre-et al were unable to find any correlation between severity
of liver disease and HCV genotype [17]. However, to vent the nosocomial spread of HCV infection in dialysis
units has been a subject of considerable debate for sev-date, the impact of HCV genotype on patient survival
in ESRD has not been reported. The results of our study eral reasons (abstract; Garcia-Valdescasas, J Am Soc
Nephrol 4:347, 1993) [37]. First, timely isolation of newlyfailed to show an important role for HCV genotype in
survival among ESRD patients with HCV infection. The infected dialysis patients with HCV is handicapped by
the lack of sensitive tests that identify the early stagesRR of death for patients infected with genotype 1a, 1b,
or others was not significantly different from each other. of HCV infection [38]. Indeed, the initial presentation
of hepatitis C in dialysis patients is often associated withThis study was conducted at 14 centers and encom-
passed over a decade of observations, during which im- a subtle clinical picture, fluctuating levels of serum trans-
aminases, and a significant delay in anti-HCV antibodymunosuppressive protocols constantly changed. To ex-
plore the possible effect of these factors on patient production [38, 39]. Furthermore, detection of HCV
RNA by PCR, considered to be the “gold standard” forsurvival, we included the transplant center as a stratifica-
tion variable in the regression model. However, this did the diagnosis of HCV infection, is costly, available only in
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select laboratories, and therefore unlikely to find routine type and number of HCV genotypes may not have a
application in clinical practice [40]. Second, enforcement significant impact on survival among ESRD patients. In
and strict adherence to universal precautions and rigor- particular, these observations add an additional measure
ous infection-control measures alone have proven to be of confidence to the policy of using organs from anti-
sufficient to control the spread of HCV infection in dial- HCV–positive donors in patients with HCV infection.
ysis units [41, 42]. Third, the isolation of anti-HCV–
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